Indaptus reports Phase 1 interim data for Decoy20: biomarker activation & transient AEs in first cohort

Indaptus Therapeutics, Inc.

Interim data from first cohort (n=4) of Phase 1 INDP-D101 trial for Decoy20, dosed at 7x10^7 killed bacteria via 1-hour IV infusion.
Treatment-related AEs included changes in hemodynamic parameters, transaminase elevations, lymphopenia; all resolved within 30 min to 3 days.
Transient activation of innate and/or adaptive immune biomarkers observed in all patients as of Aug 31, 2023.
Company to present full interim data at SITC 38th Annual Meeting on November 4, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.